



MPS PHARMA LIMITED

(FORMERLY ADVIK LABORATORIES LIMITED)

Dated: 17/01/2026

To,
The Manager (Listing),
BSE Limited,
01st Floor, P. J. Towers,
Dalal Street,
Mumbai – 400001

Subject: Statement of Investor Complaints for the quarter ended 31st December, 2025

Ref: BSE Scrip Code– 531686; ASE Scrip Code– 01636 (ADVIK LABO)

Dear Sir,

As per the requirements of Regulation 13(3) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find herein below the Statement of Investor Complaints for the quarter ended 31st December, 2025 for your kind perusal:

Number of Investor Complaints pending at the beginning of the quarter ending on 31 st December, 2025, i.e. on 01 st October, 2025	Number of Investor Complaints received during the quarter ending on 31 st December, 2025, i.e. from 01 st October, 2025 to 31 st December, 2025	Number of Investor Complaints disposed of during the quarter ending on 31 st December, 2025, i.e. from 01 st October, 2025 to 31 st December, 2025	Number of Investor Complaints remaining unresolved at the end of the quarter, i.e. on 31 st December, 2025
NIL	NIL	NIL	NIL

This is for your information and records please.

Thanking You.

Yours Faithfully,
For MPS Pharma Limited
(Formerly Advik Laboratories Limited)

Pooja Chuni
Company Secretary

CC:

The Manager (Listing)
Ahmedabad Stock Exchange Ltd.,
01st Floor, Kamdhenu Complex,
Opp. Sahajanand College, Panjrapole,
Ambawadi, Ahmedabad - 380015

CIN No. : L74899HR1994PLC038300

Corporate Office : 703, Arunachal building 19, Barakhamba Road, Connaught Place, New Delhi 110001

Phones: 011-42424884, 43571040-45, Fax: 011-43571047

Regd. Office & Factory: 138. Roz-Ka-Meo Industrial Area, Sohna - 122103 (Distt.Mewat), Haryana
Phones: 0124-2362471 Email:info@mpspharma.com Website: www.mpspharma.com